AVROBIO, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 24.96 million compared to USD 29.83 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.68 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.9 USD | -3.46% |
|
-1.24% | -2.57% |
20/06 | Avrobio Closes Merger With Tectonic Therapeutic | MT |
20/06 | Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.57% | 234M | |
+15.82% | 122B | |
+20.35% | 114B | |
+17.47% | 25.71B | |
-25.31% | 19.02B | |
-19.51% | 15.83B | |
-19.67% | 15.32B | |
-46.87% | 14.88B | |
+62.55% | 14.82B | |
+6.34% | 14.1B |
- Stock Market
- Equities
- AVRO Stock
- News Tectonic Therapeutic, Inc.
- AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023